Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer recurrence.
Prostate Cancer
Latest News
Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
![ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC](https://www.guoncologynow.com/cdn-cgi/image/w=240,h=240,q=85,f=auto,fit=scale-down,width=640/https://mumcdnstorage.blob.core.windows.net/guonc/2022/12/Prostate-3.0.png)
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Latest News
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.